Hiroshi KAWAI, Ph.D.
Board Director CEO
Kyoto Univ., Ph.D.(Biochemistry),
Mitsubishi Tanabe, Mitsubishi Tanabe Holdings America
Led Business Development for 15 years
2019/10 Director of Socium.
2020/6 Board Director of Socium
Katsuhisa HORIMOTO, Ph.D.
Board Director CTO, Funder
Tokyo Univ. of Science, Ph.D.(Biophysics),The Univ. of Tokyo, AIST
>130 peer-reviewed papers on computational systems biology, 8 parents of algorithms
2017/9 CTO, Co-founder of Socium
2019/4 Invited Researcher of AIST, Visiting Professor of Saitama Medical Univ.
Maiko KATADAE, Ph.D.
Ochanomizu Univ., The Univ. of Tokyo, Ph.D.(Science)
She was involved in investment in biotechnology and healthcare ventures at University of Tokyo Edge Capital Partners (UTEC).
Equity research, R&D finance, Portfolio management, BD support.
2021/2 Outside Director of Socium
Director Business Development
Nihon Univ., MS(Pharmacy)
Kyorin Pharmaceuticals, Kyorin USA Led Development project and US operation.
2021/1 Director of Socium
Masashi KITAZAWA, Ph.D.
Astellas Pharma, AIST,
Led drug target discovery projects in academic and corporate research
2018/4 Manager of Socium.
2019/10 Director of Socium
Director Corporate Administration
Yokohama City Univ.,BA.(Accounting),KPMG AZSA LLC, SCS consulting HK.
Led Audit, financial advisory, listed in HK Main Board as IPO project manager
2019/6 Director of Socium
Atsushi USAMI, Ph.D.
Tokyo Univ.,Ph.D.(Pharmaceutical Science)
Worked at Mitsubishi Research Institute, Inc., in charge of the development of new business strategies and management plans in the life science sector.
Joined University of Tokyo Edge Capital Partners (UTEC) in October 2013. At present, a director and partner in charge of seed/early stage investments and management support.
Also a supporter of the Life Science Innovation Network Japan (LINK-J).